Urinary tract infections (UTI) comprise about one-third of all healthcare-associated infections (HAI) – an infection that develops as a result of medical care. They are the fifth most common type of HAI, with an estimated 62,700 cases in acute care hospitals in 2015, causing 13,000 fatalities annually.
Urinary tract infections involve any part of the urinary system, including kidneys, ureters, bladder, and urethra. UTIs are more common and complicated than many perceive, with approximately 22% of the cases remaining undiagnosed or misdiagnosed. Left untreated, urinary tract infections can cause long-term effects on the interconnected gastrointestinal tract, vagina, and general urinary system.
The American Urological Association estimates that 150 million urinary tract infections occur worldwide yearly, costing up to $6 billion in healthcare expenses. Often accompanied by unintended use of antibiotics, recurrent UTIs result in many multi-drug resistance (MDR) pathogens.
Scientists are exploring novel and integrated approaches to holistically viewing urinary tract infections as a patient-centric issue and understanding its natural environment by utilizing advanced systems biology applications, transcriptomics, in silico metabolic modeling, and precision medicine practices.
Current and proven tools available include quick, reliable diagnostic tests like Acutis Reveal™ UTI. Our urinary tract infection test offers a proven, state-of-the-art technique that uses PCR-based testing methodology to diagnose infections caused by both gram-negative and gram-positive pathogens. Followed by antibiotic sensitivity testing (AST) information to prevent potential overuse or inappropriate use of antibiotics, Acutis Reveal™ UTI provides enhanced accuracy and treatment insights.
Click here to access the full article.
Comments